Piper Sandler Maintains Neutral on Edwards Lifesciences, Raises Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains a Neutral rating on Edwards Lifesciences (EW) and raises the price target from $85 to $88.
April 26, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Edwards Lifesciences and raises the price target from $85 to $88.
The increase in price target by Piper Sandler suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, balancing the potential impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90